2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada

To revise and expand the 1996 Osteoporosis Society of Canada clinical practice guidelines for the management of osteoporosis, incorporating recent advances in diagnosis, prevention and management of osteoporosis, and to identify and assess the evidence supporting the recommendations. All aspects of...

Full description

Saved in:
Bibliographic Details
Published in:Canadian Medical Association journal 2002-11, Vol.167 (90100), p.S1-34
Main Authors: Brown, Jacques P, Josse, Robert G
Format: Article
Language:English
Subjects:
Adult
Aged
Bone Density
Canada
Child
Diet
Diphosphonates - therapeutic use
Estrogens, Non-Steroidal
Female
Humans
Isoflavones
Male
Management
Medical diagnosis
Middle Aged
Osteoporosis
Osteoporosis - diagnosis
Osteoporosis - drug therapy
Osteoporosis - prevention & control
Phytoestrogens
Plant Preparations
Practice Guidelines as Topic
Prognosis
Randomized Controlled Trials as Topic
Risk Factors
Supplement
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To revise and expand the 1996 Osteoporosis Society of Canada clinical practice guidelines for the management of osteoporosis, incorporating recent advances in diagnosis, prevention and management of osteoporosis, and to identify and assess the evidence supporting the recommendations. All aspects of osteoporosis care and its fracture complications - including classification, diagnosis, management and methods for screening, as well as prevention and reducing fracture risk - were reviewed, revised as required and expressed as a set of recommendations. Strategies for identifying and evaluating those at high risk; the use of bone mineral density and biochemical markers in diagnosis and assessing response to management; recommendations regarding nutrition and physical activity; and the selection of pharmacologic therapy for the prevention and management of osteoporosis in men and women and for osteoporosis resulting from glucocorticoid treatment. All recommendations were developed using a justifiable and reproducible process involving an explicit method for the evaluation and citation of supporting evidence. All recommendations were reviewed by members of the Scientific Advisory Council of the Osteoporosis Society of Canada, an expert steering committee and others, including family physicians, dietitians, therapists and representatives of various medical specialties involved in osteoporosis care (geriatric medicine, rheumatology, endocrinology, obstetrics and gynecology, nephrology, radiology) as well as methodologists from across Canada. Earlier diagnosis and prevention of fractures should decrease the medical, social and economic burdens of this disease. This document outlines detailed recommendations pertaining to all aspects of osteoporosis. Strategies for identifying those at increased risk (i.e., those with at least one major or 2 minor risk factors) and screening with central dual-energy x-ray absorptiometry at age 65 years are recommended. Bisphosphonates and raloxifene are first-line therapies in the prevention and treatment of postmenopausal osteoporosis. Estrogen and progestin/progesterone is a first-line therapy in the prevention and a second-line therapy in the treatment of postmenopausal osteoporosis. Nasal calcitonin is a second-line therapy in the treatment of postmenopausal osteoporosis. Although not yet approved for use in Canada, hPTH(1-34) is expected to be a first-line treatment for postmenopausal women with severe osteoporosis. Ipriflavone,
ISSN:0008-4409
0820-3946
1488-2329